Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Multimodality treatment provides modest survival benefits for patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC). Nevertheless, preoperative immunotherapy has continuously been shown to be promising in treating resectable NSCLC.This phase 2 trial enrolled patients with AJC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ze-Rui, Yang, Chao-Pin, Chen, Si, Yu, Hui, Lin, Yong-Bin, Lin, Yao-Bin, Qi, Han, Jin, Jie-Tian, Lian, Shan-Shan, Wang, Yi-Zhi, You, Jin-Qi, Zhai, Wen-Yu, Long, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547836/
https://www.ncbi.nlm.nih.gov/pubmed/34712513
http://dx.doi.org/10.1080/2162402X.2021.1996000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547836/
https://www.ncbi.nlm.nih.gov/pubmed/34712513
http://dx.doi.org/10.1080/2162402X.2021.1996000

Ejemplares similares